Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies

Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies

Patients with hematologic malignancies are reported to have a more severe course of coronavirus disease 2019 (COVID-19) and be less responsive to vaccination. In this prospective study, we aimed to evaluate the serological responses to booster COVID-19 vaccines of Taiwanese patients with hematologic...

Full description

Bibliographic Details
Main Authors: Chien-Tzu Huang, Ching-Ping Lee, Tzu-Yin Chen, Yi-Chang Liu, Shih-Feng Cho, Jeng-Shiun Du, Ming-Lung Yu, Chung-Feng Huang, Sheng-Fan Wang, Hui-Hua Hsiao
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Journal of Clinical Medicine
Subjects:
coronavirus disease 2019
booster vaccines
hematologic malignancies
B-cell-targeted agents
hypogammaglobinemia
Online Access:https://www.mdpi.com/2077-0383/12/17/5647

Similar Items

Similar Items